How many institutional investors hold ACAD?

4 tracked institutional investors disclosed a position in ACAD (ACADIA PHARMACEUTICALS INC) in their most recent 13F filing.

Who is the largest institutional holder of ACAD?

Steve Cohen, Point72 Asset Management, holds the largest disclosed position in ACAD, valued at $90M.

Where does this ACAD ownership data come from?

SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.

ACAD — ACADIA PHARMACEUTICALS INC

Name: ACADIA PHARMACEUTICALS INC (ACAD) — Institutional Ownership
Creator: InvestorLens
License: https://www.sec.gov/about/website-policies

Public company

For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

About ACADIA PHARMACEUTICALS INC (ACAD)

ACADIA PHARMACEUTICALS INC (ACAD) appears in the most recent 13F filings of 4 tracked institutional investors. The largest disclosed position is held by Steve Cohen (Point72 Asset Management), valued at $90M. Across recent filings, tracked investors recorded 6 new positions, 2 increased, 2 reduced, and 0 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in ACAD

/100

Strong Institutional Accumulation

Added / Increased8

Reduced2

Exited0

BearishBullish

Crowded Trade Score™

How many top investors track ACAD

/100

Emerging Interest

4investors

A small number of top investors own this.

UndiscoveredCrowded

151015+

ACAD Ownership Composition

How ACADIA PHARMACEUTICALS INC is held across tracked investor types, based on reported 13F positions.

Dominant Type

Hedge Funds

63% of tracked value

Institutions

tracked investors

Total Reported

$91.5M

combined 13F value

Hedge Funds63.4%
Other36.6%

Hedge Funds(1)

63.4%

Other(3)

36.6%

Tracked investors reporting ACAD

Investor	Firm	Shares	Market value	% of portfolio	As of
Steve Cohen	Point72 Asset Management	2.6M	$58M	0.07%	Mar 31, 2026
Ken Griffin	Citadel Advisors	658.7K	$14.7M	0.00%	Mar 31, 2026
Izzy Englander	Millennium Management	705.5K	$15.7M	0.01%	Mar 31, 2026
Ray Dalio	Bridgewater Associates	141.8K	$3.2M	0.01%	Mar 31, 2026

Steve CohenMar 31, 2026
Point72 Asset Management
Shares
2.6M
Value
$58M
% Portfolio
0.07%
Ken GriffinMar 31, 2026
Citadel Advisors
Shares
658.7K
Value
$14.7M
% Portfolio
0.00%
Izzy EnglanderMar 31, 2026
Millennium Management
Shares
705.5K
Value
$15.7M
% Portfolio
0.01%
Ray DalioMar 31, 2026
Bridgewater Associates
Shares
141.8K
Value
$3.2M
% Portfolio
0.01%

Recent activity

Investor	Action	Δ %	Current value	Filing date
Izzy Englander	New	—	$14.8M	Feb 17, 2026
Izzy Englander	New	—	$15.7M	May 15, 2026
Steve Cohen	New	—	$90.2M	Feb 17, 2026
Ken Griffin	Reduced	-53.14%	$14.7M	May 15, 2026
Steve Cohen	New	—	$58M	May 15, 2026
Ray Dalio	Increased	2.63%	$3.2M	May 15, 2026
Ken Griffin	Increased	183.40%	$37.5M	Feb 17, 2026
Ray Dalio	Reduced	-15.35%	$3.7M	Feb 13, 2026
Ken Griffin	New	—	$10.6M	Nov 14, 2025
Ray Dalio	New	—	$3.5M	Nov 13, 2025

Izzy Englander
New
$14.8MFeb 17, 2026
Izzy Englander
New
$15.7MMay 15, 2026
Steve Cohen
New
$90.2MFeb 17, 2026
Ken Griffin
Reduced
$14.7M(-53.14%)May 15, 2026
Steve Cohen
New
$58MMay 15, 2026
Ray Dalio
Increased
$3.2M(2.63%)May 15, 2026
Ken Griffin
Increased
$37.5M(183.40%)Feb 17, 2026
Ray Dalio
Reduced
$3.7M(-15.35%)Feb 13, 2026
Ken Griffin
New
$10.6MNov 14, 2025
Ray Dalio
New
$3.5MNov 13, 2025

Frequently asked questions

How many institutional investors hold ACAD?: 4 tracked institutional investors disclosed a position in ACAD (ACADIA PHARMACEUTICALS INC) in their most recent 13F filing.
Who is the largest institutional holder of ACAD?: Steve Cohen, Point72 Asset Management, holds the largest disclosed position in ACAD, valued at $90M.
Did institutional ownership of ACAD increase or decrease?: Across recent 13F filings, tracked investors recorded 6 new positions, 2 increased, 2 reduced, and 0 fully exited ACAD.
Where does this ACAD ownership data come from?: SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.